<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 380 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page379.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=380">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 380 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 380</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=380"><img src="../thumb/380.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Others - 29                                                                    2020-04 / 343
       freq. of admin., use low.effect.dose, vir.infect. transmiss.poss.due   pit., urticar. Chew gum also: Jaw musc.ache, traum.to oral mucosa/  Indications: Substit.treatm.for opioid drug depend. within medic./
       to pres.of human albumin, admin. only by exper.special.in hosp.  teeth, burn.tong.sensat.  soc./psycholog. framework in adults & adolesc.over 15 yrs.con-
       adeq.equip.for resuscit.and anphylax.treatm., spec.att.to storage,   Warnings and special precautions: Keep out of reach of childr.at   sent.to addict. treatm. The intention of the naloxone content is to
       poss.anaphylact.react., poss.vis.disturbs., antibody format.detect.  all times, do not smoke dur. treatm., adapt.dos.if used to supplement   deter IV misuse.
       by deterioriat.in respons.to treatm. theref.reconsid.treatm.in these   behav. tobacco withdr.progr., ser.CV event/hospital.dur. prev. 4 wks.for   (S6) SUBLING.TABS. 41/34/1010
       instances, excess muscul.weakn.result from incr.sensitiv.in pts with   CV complaint, stroke, MI, unstable ang., coron.art.bypass graft & an-  Buprenorphine HCl 2 mg, naloxone HCl dihydrate 0,5 mg
       subclinic /clinic.evid.of neuromusc.transmiss., electromyography   gioplasty, ser. card.arrhythm., vasosp.dis., sev.to mod.hepat. impairm.,   714063-001: 7 , R105,90
       may help identify act.musc., deactiv. any spill.or vial/syringe resid.  sev.ren.impairm., act.duod./gastr. ulc./pept.ulc., occlus.periph.arter.  (S6) SUBLING.TABS. 41/34/1011
       with dil. hypochlorite sol., pre-exist.swallow/breath./ speech prob-  dis., HF, syst./ uncontrol. hypertens., discont.patches in case of sev./   Buprenorphine HCl 8 mg, naloxone HCl dihydr.2 mg
       lems., only admin.if benef.outweigh risk in pts.with disords.result.  persist. skin reacts., not for non-smok., uncontrol. hyperthyroid., phae-  714064-001: 7 , R424,87
       in defect.neuromusc. transmiss.  ochromocyt., diab.mellit., poss.low.insul.dos.with smok.cessat., cer-  Dosage: Ther.und.supervis.of phys.exper.in opiate depend./addict.
       Drug interactions: Eff.pos.potent.by aminoglycos./ other drugs   ebrovasc. insuff., smok. pts undergo. haemodialys.exper.high. nicotine   Admin.subling until dissolv.(usual. 5-10 mins). Undertake treatm.when
       interf.neuromusc. transmiss.  levs., Chew gum also: oral/pharyng.inflamm., oesophagit., dentures,   object.& clear signs of withdr.evid.
       See also MDR page 449.        retain any spare tabs as crav.may sudden. occur, seek profess.advice   Init.ther: Recomm.start.dos 1-2 tabs (of 2/0,5 mg strength). An ad-
       JAKAVI, Novartis [P/S]        if reduct.in number of cigarettes not achiev.aft.6 wks., poss.diarrh.&   dit. 1-2 tabs (of 2/0,5 mg strength).may be admin.on day 1 depend.
                                                                  on indiv. requirem.
                                     flatul. from xylitol content in some presentat., heredit. fruct.intol.
       Ruxolitinib                   Interactions: Poss.alter.respons.to concom.meds. in ex-smokers,   Opioid-depend.pts.who have not undergone withdr: Admin.1   st
       Indications: Dis.relat.splenomegaly/sympts in adults with prim.  smok.cessat.may incr. bld. lev.of phenacetin/caff./theophyll./imi-  dos.when first signs of withdr. appear. but not less than 6 hrs aft.
       myelofibros./post polycythaem. vera myelofibros or post essent.  pramine/ pentazocine/tacrine/clozapine/ropinirole/ olanzapine/  last opioid use.
       thrombocythaem. myelofibros.                               Pts receiv.methadone: Bef.init.ther.methadone dos.to be reduc.to
       (S4) TABS, 48/34/0109, 0110, 0111  clomipramine & fluvoxamine, decr.absorpt.of glutethimide, first   max.of 30 mg/day. Admin.1  dos. when first signs of withdr.appear.
                                                                              st
                                     pass metabol.of propoxyphene decr., smok.reduc.furosemide diu-
       720732-001: 5 mg, 56, R18 868,70  ret. eff.& decr.card.output, & incr.BP with propranolol which may be   but not less than 24 hrs aft.last methadone use.
       720731-001: 15 mg, 56, R37 733,64  revers.with smok.cessat., circulat. lev. of cortisol & catecholamines   Adjustm.& maint: Indiv. Incr.progress.accord.to effect to max.sngl.
       720730-001: 20 mg, 56, R37 733,64  incr.requir.poss. dos.adjustm.of adrenerg.agon./adrenerg.block. with   dly dos.of 24 mg. Titr.dos. accord. to clinic.& psycholog.status in steps
       Dosage: Complete bld. count.bef.init.ther.& monit.2-4 wkly.un-  of 2-8 mg. Dispens.treatm.init.on dly.basis. Aft. stabilisat.& bas.on
       til dos.stabilis.             changes to nicotine ther./smok.status, pentazocine & flecainide.me-  pt.reliabil.supply of sev.days limit to 7 days may be giv. Aft stabilisat.
                                     tabol.poss.induc.by smok.
       Recom.start.dos: 15 mg 2xdly with platelet count 100 000-200 000/  dos.freq. may be decr.to every other day at dose twice the indiv. titrat.
       mm  & 20 mg 2xdly with platelet count &gt;200 000/mm , Limit.info in   QUIT, (Aspen Pharmacare: Consum) Pharmacare [P/S]  dly dos.with no medicat.on interven. days. Dos. on any one day not to
                             3
         3
                               3
                        3
       pts with platelet count betw.50 000/mm & 100 000/mm  so max.   Nicotine.  exceed 24 mg. See manufact.lit.for 3x/wk dos.regim.
       recomm. start.dos is 5 mg 2xdly with cautious titrat.  Indications: Temp.aid to stop smoking in nicotine depend.smokers   Dos.reduct.& terminat: Reduc.dos.grad.aft. satisfact. stabilisat.
                                  3
       Dos modificat: Interupt.if platelet counts less than 50 000/mm  or   in conjunct.with cessat.program.  period achiev.& discont.when appropr. Monit.aft.terminat.because
       absol.neutrophil count less than 500/mm . Aft.bld.count recov.above   (S2) MET.DOS SPRAY SOL. 29/34/0392.  of relapse potent.
                        3
       these lev.restart at 5 mg 2xdly.incr.grad.bas.on bld.cell counts. Reduc.  Quit 1: 1 mg, Quit 2: 0,66 mg, Quit 3: 0,33 mg., Quit 4: no nico-  Contraindications: Sev.resp./hepat.insuffic., ac.alcohol., delir-
       dos.if platelet counts decr.below 100 000/mm  to avoid dos.interrupt.  tine/met.dos  ium tremens, safety & effic.in elderly pts.&gt; 65 yrs not est., childr.
                          3
       for thrombocytopen. If effic.consid.insuffic.& platelet & neutrophil   836079-019: 4x20 ml, R405,28  und.15 yrs., buprenorphine/ naloxone hypersens.hist., concom. al-
       counts adeq.dos.may be incr.by a max.of 5 mg 2xdly.  Dosage: Quit 1 recomm.when 20 or more cigaret./ day.are smok.   coh./ meds.contain.alcoh.
       Do not incr.start.dos.within 1  4 wks.& thereaft. not more freq.than   Spray 1-2 dos.in mouth whenev.urge felt. Usual.20-24 sprays/day.   Side effects: Withdr.syndr.in neonat.whose mothers used chronic.
                   st
       at 2 wk.interv. Max.dos: 25 mg 2xdly. If dos.miss.do not take addit.  Max.60 met.sprays/ 24 hrs.  dur.last 3 mnths.of pregn., infect., vaginit., bld.dyscras., allerg.re-
       dos.but take the next usual prescrib.dos.  Quit 2 recomm.when smok.up to 20 cigaret./day. Max 90 met.  acts., periph. oed., decr.weight/libido, insomn., hyperglycaem., hy-
       Contraindications: Pregn.& lactat.  sprays/24 hrs.         perlipidaem., hypoglycaem., psych.disords.incl. drug depend & dep-
       Side effects: Most freq: Thrombocytopen., anaem. & neutro-  Quit 3 reduc.nicotine substitut.towards end of ther.  ersonalisat., somnol., drowsin., dizzin., paraesthes., convuls., trem.,
       pen., bruis., dizzin.& headache. Very common: UTI’s, hypercho-  Quit 4 used aft Quit 3 used  hyperkines., lacrimat., amblyop., mios., conjunctivit., MI, ang. pect.,
       lesterolaem., rais. alan.& aspart.aminotransfer. Common: H Zos-  Aft.3-4 wks.of withdr.if respons.satisfact.cont. with next low.dos for   palpitat., tachycard., bradycard., vasodilat., hypertens., migraine, hy-
       ter, weight gain, flatul.     3-4 wks. & then another dos.reduct.to low dos.  potens., heat stroke, rhinit., pharyngit., incr.cough, dyspn., asthma,
       Warnings and special precautions: Complete bld. count.bef.init.  Contraindications: Childr.und.18 yrs., non/ occas. smokers, ac MI,   yawn., GI disturbs., tong.discol., ulc.stomatit., abnorm.liv.funct., skin
       ther.& monit., thrombocytopen. more likely to develop if low platelet   immed.post MI period, sev. or unstab.ang.pect., sev.card.arrythm.,   reacts.incl.exfoll.dermatit., alopec., sweat., arthralg., myalg., leg
       counts observ. at start of ther., thrombocytopen.gen. revers. manag.  recent CVA, pregn. & lactat., pts.who cont.to smoke.  cramps, arthrit., urine abnormalit., kidn.calcul., incr.creatin., UTI,
       by dos.reduct./tempor.withhold.or poss.platelet transfus., poss.dos.  Side effects: Mouth, throat irrit., incr.salivat., GI disturbs., dry mouth,   dysur., urin.retent., impot., abnorm.ejaculat., amenorrh., menorrhag.,
       modificat./bld. transfus.for anaem., neutropen.gen.revers.& manag.   CNS eff., flush, sneez., cough, euphor., insomn., ment.confus., vis.&   metrorrhag., withdr.syndr., headache, asthen., fev., flu syndr., malaise,
       by tempor.withhold., monit.pt.infect.risk & ser. infect.to be resolv.  hear. disturbs., dyspn., dizzin., eructat., jaw musc.ache, atrial fibrillat.,   accid. inj., chills, chest/abdom./back pain, hypotherm., hyperhidros.,
       bef.init.ther., sev.ren. impairm., hepat.impairm., reduc.dos.by ap-  exacerb.sympts.of gastr./pept.ulc.  periph.oed., loc.reacts.with drug abuse/misuse, ac./cytolyt.hepatit.,
       prox. 50% if strong CYP3A4 inhibit.co-admin.& monit.for cytopen.,   Special precautions: Keep out of reach of childr. at all times, no   pneum., endocardit., other ser.infects., death from resp. depress.esp.
       lact.intol., reoccur.of myelofibros.relat. sympts.on discont., women   smok.dur.treatm., chron.use, hypertens., ang.pect., cerebrovasc.in-  with concom.benzodiazepin./other depress./when not used accord.
       of child.bear.potent.to avoid pregn.dur.ther., safety & effic.in paed.  suff., occlus. periph. arter.dis., HF, hyperthyroid., diab.mellit., ren./   to prescrib.info., hypersens.reacts.incl. anaphylact.shock, jaund.,
       not est., advise pt.about early signs & sympts.of H.Zoster and to   hepat.insuff., oesophag./pept.ulc., oral/ pharyng. inflammat.  hepatoren.syndr., hepat.encephalopathy/necros., vertigo, init. bu-
       seek treatm.as early as poss.  Drug interactions: Poss.alter.respons.to concom. meds.in ex-  prenorphine admin.may produc. withdr.eff.simil.to that assoc.with
       Interactions: Strong CYP3A4 inhibit.incr.AUC and prolong half-life,   smokers, smok.cessat.may incr.bld. lev.of phenacetin, caff., theo-  naloxone in pts. present. with mark.drug depend., spontan.abort.
       AUC and half-life decr.with CYP3A4 induc.  phyll., imipramine & pentazocine, decr.absorpt.of glutethimide, first   although caus.relationship not est.
       NICORETTE, J&J [P/S]          pass metabol.of propoxyphene decr., reduc.diuret. effs.of furosem.  Warnings and special precautions: Reproduct. toxic.in animals,
       Nicotine                      decr.card.output, incr.BP with propranolol, circulat.lev.of cortisol   pregn.& lactat., monit.mother & unborn foet./switch ther.to buprenor-
                                                                  phine if pregn. occurs, neonat.monit.at end of pregn.prevent.resp.
       Indications: Temp.aid to stop smoking in conjunct. with behav-  & catecholamin. incr. dos.adjustm.of adrenerg.agon./adrenerg.
       iour.modificat.program.       block. poss.necess.          depress. risk/withdr.sympt.in neonat., adolesc.15-18 yrs. due to lack
       (S1) CHEW.GUM, [P/S] P/34/187  Warning: Discont.if sympts.of nicotine OD appear, poss. transf.  of data, monit.pts.dur.switch. per. from buprenorphine or methadone,
                                                                  protect childr. against expos., pharmacol.&/phys.risk fact., compromis.
       747106-010: 2 mg, 30, R126,33  nicotine depend.
       747106-002: 2 mg, 105, R193,31  RILUTEK, Sanofi-Aventis [P/S]  resp.funct., mod.to sev.hepat.impairm., sev. ren.impairm., head injury,
                                                                  incr.IC/cerebrospin. press., seiz.hist., myxoed., hypothyroid., adrenocort.
       (S1) MINT CHEW.GUM, [P/S] 30/34/0272  Riluzole.
       701843-006: 2 mg, 105, R186,27  Indications: Surviv.extens.in pts.with bulbar variant of motor   insuffic., tox.psychos., ac.alcohol., delirium tremens, hypotens., pros-
                                                                  tat.hypertrophy, urethr. strict., bil.tract dysfunct., elderly/debilit. pts.,
       Dosage: 10-12 pieces dly.chew.slow.over 30 mins. one at a time   neuron dis.  concom.MAOI poss.produc.exaggerat.of opioids effs., pts.to be warn.
       when urge to smoke felt. Max. 15 pieces in 24 hours. Reduc.num-  (S4) TABS. 30/34/0229.
       ber chew. each day as urge to smoke fades, usual.poss. within 2-3   824100-018: 50 mg, 56, R6 510,86  of extrem.ser.effs. with non-prescrib.benzodiazepin., subling.is only
                                                                  effect. & safe admin.route, baseline LFT/vir. hepatit. status recomm.,
       mnths. Stop only once crav.satisf.with 1-2 pieces dly. Do not use   Dosage: 50 mg 12 hrly.1 hr.bef./2 hrs.aft.meals.
       for more than 3 mnths.        Contraindications: Act.hepat.dis./baseline transaminas. &gt;3xULN,   accelerat.liv.inj.risk with posit. vir. hepatit./concom.meds or exist.liv.
                                                                  dysfunct., reg.hepat.funct.monit.recomm., diversion risk, sub-optim.
       (S1) TRANSDERM.(TTS) PATCHES, [P/S] 45/32.16/0952, 0953, 0954  safety in pregn.& lactat.not est., safety & effectiven.in any neurode-
       3000111-001: 10 mg/16 hrs., 7, R192,66  generat. process in childr./adolesc.not est.  treatm.poss.prompt.meds. misuse, monit.pts.with phys.&/pharma-
                                                                  colog.risk fact., depend., poss.delay.withdr.syndr.aft.discont., pre-exist.
       3000110-001: 15 mg/16 hrs., 7, R192,66  Side effects: Dizzin., vertigo, somnol., N&V, GI disturbs., rectal dis-  mitochondr.impairm.poss.contrib.in ac. hepat. events, precipit.withdr.,
       3000088-001: 25 mg/16 hrs., 7, R192,66  ords., pseudomembr. enterocolit., pept.ulc.haemorrh., oral monilias.,   opioid-induc.mios./ change in consciousn.lev./pain percept.as sympt. of
       Dosage: Adults & elderly: Apply to intact skin in the morn.& remov.  headache, oral paraesthes., amnes., coma, depress., hyperton., as-  dis.poss.interfer.with pt.eval./obscure diagn.or clinic. course of concom.
       at bedt. Gen.not recom.to use patch beyond 6 mnths.  then., pain, chest/ back pain, malaise, eczema, nail disords., prurit.,   dis., overdos.potent., concom. potent CYP3A4 inhibit./induc., furth.eval.
       Heavy smok.start with step 1 of 1x25 mg patch dly. x8 wks. Wean   alopec., exfoliat.dermatit., tachycard., hypertens., arrhythm., postur.  need.if hepat.event susp., monit.liv.funct.should treatm. contin.based
       grad.with 1x15 mg patch dly x2 wks. follow.by 1x10 mg patch dly   hypotens., decr.lung funct., pneum., arthralg., UTI, dysur., anaem.,   on biolog./etiolog.find., buprenorphine excret.in breast milk, incr. intra-
       x2wks. Light smok. start with step 2 15 mg x8 wks.& decr.to step   neutropen., periph. oed., weight loss, liv.funct.test abnorm., hepatit.,   choledoch. press., orthostat.hypotens.in ambulat. pts., CSF poss.elevat.,
       3 10 mg for final 4 wks.      anaphyl.react., angio-oed.   hepat.fail./necros./ encephalopathy, poss.death, buprenorphine poss.
       Contraindications: Childr.und.18 yrs., non-/occas. smokers,   Special precautions:, Discont.if ALT lev.incr.5x to ULN.(dos.  precip. withdr.sympt.in pts.depend.on methadone.
       pregn.& lactat., immed post MI period (within 3 mnths), sev.life-  reduct.& rechall.not recomm.in this situat.), ren insuffic., liv.im-  Drug interactions: Depress.eff.potent.by CNS-depress.incl.alcoh./
       threat.card. dysrhythm., sev./worsen.ang.pect., Prinzmetal’s vari-  pairm., febr.ilness.  other opioid derivats.e.g. antituss./ cert.anti-depress./H 1 recept.anta-
       ant ang., pregn.& lactat., women plan.pregn., stroke in ac.phase,   Drug interactions: Decr.eff.with CYP 1A2 inhibits., incr.eff.with   gon./ barbits./ anxiolyt.other than bezodiazepin./ neurolept./ clonidine
       act.temporo-mandibul.joint dis. Patch also: Skin hypersens., gen.  CYP 1A2 induc.  & relat.subst., poss.death due to resp.depress.with benzodiazepin.,
       skin disords.                 Warnings: Incr.ALT appear within 3 mnths.aft start of ther., usual.  reduc. analges. eff.of other opioids e.g.methadone/lev. 111 anal-
       Side effects: Allerg.reacts.incl.angioed., cough, CNS eff., throat   trans.& levs.return.below 2XULN aft.2-6 mnths.with contin.treatm.,   ges., poss.block.buprenorphine pharmacolog. effs.with naltrexone,
       & mouth irrit., dry mouth & throat, chest/ skelet.pain, GI disturbs.,   incr. assoc. with jaund., meas.serum transaminas. incl. ALT bef.,every   incr. C max & AUC with potent CYP3A4 inhibit., reduc.buprenorphine
       incr.sweat., leg musc. cramps, musc.pain in extrem., nicotine taste/   mnth dur.1st 3 mnths, every 3 mnths. dur.remain.of 1st yr.& period.  plasma conc.with CYP3A4 induc.
       smell, incr.salivat., hiccough, hoarsen., flush., sneez., eructat, nico-  thereaft., freq. monit. of ALT.levs.in pts who develop.elev.ALT lev.  See also MDR page 383.
       tine depend., rhinit., Freq: Dizzin., headache, poss.incr.freq.aphthous
       ulc., GI discomf., N&V, constipat., itch.erythema with patches. Less.  SUBOXONE, (AI Crit Care) Indivior [N/P/S in C] &  SUBUTEX, Adcock Ingram Critical Care (Pty) Ltd.
       freq: Sleep disords., vivid dreams, irritabil., revers.atrial fibrill., pal-  Buprenorphine HCl, naloxone HCl dihydrate  See Section 3.1</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page379.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page375.html">375</a>&nbsp;&nbsp;&nbsp;<a href="page376.html">376</a>&nbsp;&nbsp;&nbsp;<a href="page377.html">377</a>&nbsp;&nbsp;&nbsp;<a href="page378.html">378</a>&nbsp;&nbsp;&nbsp;<a href="page379.html">379</a>&nbsp;&nbsp;&nbsp;<a href="page380.html">380</a>&nbsp;&nbsp;&nbsp;<a href="page381.html">381</a>&nbsp;&nbsp;&nbsp;<a href="page382.html">382</a>&nbsp;&nbsp;&nbsp;<a href="page383.html">383</a>&nbsp;&nbsp;&nbsp;<a href="page384.html">384</a>&nbsp;&nbsp;&nbsp;<a href="page385.html">385</a>
             </td>
             <td width="35%"><a href="page381.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page381.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
